九洲药业(603456) - 2021 Q1 - 季度财报

Financial Performance - Operating income for the period reached RMB 856,095,409.40, an increase of 118.66% year-on-year, primarily driven by the growth in CDMO business and the resumption of production at Jiangsu Ruike[4] - Net profit attributable to shareholders increased by 190.92% year-on-year, amounting to RMB 94,404,199.00, mainly due to increased product sales revenue[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 211.31% year-on-year, totaling RMB 96,668,650.30[4] - Basic earnings per share increased by 175% year-on-year, amounting to RMB 0.11 per share[5] - Diluted earnings per share also increased by 175% year-on-year, reaching RMB 0.11 per share[5] - The company's operating revenue for Q1 2021 was RMB 856,095,409.40, an increase of 118.66% compared to RMB 391,511,397.99 in the same period last year[13] - Net profit for Q1 2021 was ¥94,680,696.08, compared to ¥32,291,050.69 in Q1 2020, representing an increase of 194.5%[23] - The total comprehensive income for Q1 2021 was ¥93,295,524.19, compared to ¥33,074,707.52 in Q1 2020[24] Assets and Liabilities - Total assets at the end of the period were RMB 5,685,476,319.42, reflecting a 13.67% increase compared to the end of the previous year[4] - The company's total assets as of Q1 2021 amounted to ¥4,361,508,878.53, up from ¥3,610,431,503.23 in the previous year, indicating a growth of 20.8%[22] - The company's total liabilities decreased to ¥549,100,211.37 in Q1 2021 from ¥810,647,210.68 in Q1 2020, a reduction of 32.2%[22] - Total liabilities reached RMB 1,915,677,518.46, with current liabilities at RMB 1,633,041,040.39 and non-current liabilities at RMB 282,636,478.07[31] - The company has short-term borrowings of RMB 788,015,823.02, reflecting its financing strategy[31] Cash Flow - The net cash flow from operating activities decreased by 87.57% year-on-year, totaling RMB 10,058,629.63, primarily due to business growth during the reporting period[4] - The net cash flow from operating activities for Q1 2021 was ¥10.06 million, a decrease of 87.6% compared to ¥80.90 million in Q1 2020[26] - The company reported cash inflows from operating activities of approximately ¥831.29 million in Q1 2021, a significant increase from ¥584.30 million in Q1 2020, representing a growth of 42.3%[26] - The company reported a significant increase in cash inflows from financing activities, totaling approximately ¥1.39 billion in Q1 2021, compared to ¥373.16 million in Q1 2020[27] Shareholder Information - The total number of shareholders at the end of the period was 14,168, with Zhejiang Zhongbei Jiuzhou Group Co., Ltd. holding 34.10% of the shares[7] - The equity attributable to shareholders increased to ¥4.17 billion from ¥3.08 billion, representing a growth of about 35.4%[20] - The total equity attributable to minority shareholders is RMB 2,907,692.07, highlighting the company's structure and stakeholder interests[32] Research and Development - The company's R&D expenses rose by 100.17%, totaling RMB 35,357,842.45, compared to RMB 17,663,551.17 in the previous year[13] - Research and development expenses for Q1 2021 were ¥35,357,842.45, compared to ¥17,663,551.17 in Q1 2020, an increase of 100.3%[23] Investment and Financing - The company completed a private placement of A-shares on January 29, 2021, raising approximately ¥993.5 million after deducting underwriting fees[16] - The company plans to use part of the raised funds to increase investment in project implementation[16] - The company reported a significant increase in investment income, which reached RMB 15,076,179.77, compared to a loss of RMB 5,041,322.67 in the previous year[14] Other Financial Metrics - The weighted average return on net assets increased by 1.36 percentage points year-on-year, reaching 2.49%[5] - The company reported a gross profit margin of approximately 29.03% for Q1 2021, compared to 26.83% in Q1 2020[24] - The financial expenses decreased significantly to ¥808,139.54 from ¥5,036,439.07 in the previous year, primarily due to lower interest expenses[25]